New Delhi, June 15 Take the example of Telangana, where health authorities recently stated that 37,332 children were infected with the virus between March and May 2021. This coupled with the fact that 19,824 children got infected from August-November 2020 tells us how we grossly underestimated the impact of Covid-19 on children.
Compared to the first wave, the number of positive cases and their severity has increased among children this time. Why is this concerning?
This is in contrast to what was earlier perceived globally that children will not suffer from the severe direct symptoms of the virus, the indirect fallout on their lives and rights is a topic for another discussion.
Direct Impact on Children
Arrival of the mutant strain, delayed diagnosis and treatment, challenge of access to healthcare services, lack of space for social distancing are making children vulnerable. Children are showing symptoms of high grade fever, severe body aches, diarrhoea, coughing and abdominal pain requiring hospitalisation. In some cases, children are also showing symptoms of multi-system inflammatory syndrome.
The fear of a third wave affecting children more than the adults has set alarm bells ringing. To safeguard children, the Union Health Ministry has listed guidelines for Covid-19 treatment for those below 18 years of age. According to government data, around 26 per cent of people infected with Covid-19 in India since May 1 are in the 18-30 age group.
Debate Is Vaccination safe for Children
Vaccination for people above 18 in India has been anything but smooth with reports of acute vaccine shortage and difficulty in registering for vaccination online. Globally, a conversation around vaccination for children has started with countries like the US taking the lead. According to the Centers for Disease Control and Prevention, 6,00,000 children in the US between age 12 and 15 have received the Pfizer shot. Studies showed that the vaccine is 100 per cent effective in kids in the same age group.
Canada, Singapore and the UAE, too, approved the Pfizer vaccine for emergency use in the 12-15 age group. Moderna is currently conducting age de-escalation studies. Johnson & Johnson also plans to do the same.
Meanwhile, in India the Phase 2 and 3 clinical trials of Bharat Biotech's Covaxin for 2-18 age group will begin in June, which will include 525 subjects across canters in AIIMS
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor